Company Filing History:
1 out of 1,929 
1 out of 86 
1 out of 43 Years Active: 2016-2020
Title: Isao Sakaida: Innovator in Regenerative Medicine
Introduction
Isao Sakaida is a prominent inventor based in Ube, Japan. He has made significant contributions to the field of regenerative medicine, particularly in the evaluation and cultivation of mesenchymal stem cells. His innovative work has led to the development of several patents that aim to improve therapeutic approaches for liver dysfunction and cancer.
Latest Patents
Sakaida holds 2 patents that focus on methods related to mesenchymal stem cells. His latest patents include a method for evaluating mesenchymal stem cell activity, which involves an assay step for measuring the amount of adenylate kinase 4 (AK4) in the cells. This method allows for the determination of the activity level of mesenchymal stem cells based on the assayed amount of AK4. Additionally, he has developed a method for culturing mesenchymal stem cells using this evaluation method, which is crucial for regenerative medicine. Furthermore, he has created a therapeutic agent for liver dysfunction, which includes a prophylactic or therapeutic agent aimed at inhibiting the onset or progress of liver cancer. This agent contains isoleucine, leucine, and valine as active ingredients, with specific weight ratios and daily dosage recommendations.
Career Highlights
Throughout his career, Sakaida has worked with notable organizations such as Ajinomoto Co., Ltd. and Yamaguchi University. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research in regenerative medicine.
Collaborations
Some of Sakaida's coworkers include Kiwamu Okita and Yoshihiro Morinaga. Their collaborative efforts have further advanced the research and development of innovative solutions in the medical field.
Conclusion
Isao Sakaida's contributions to regenerative medicine through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in therapeutic approaches for liver dysfunction and cancer.